口服免疫疗法相关家长负担量表的编制
Development of an Oral Immunotherapy-Related Parental Burden Scale.
作者信息
Maeta Akihiro, Takaoka Yuri, Hamada Masaaki, Nakano Atsuko, Sumimoto Shinichi, Anzai Kaori, Tanaka Yukiko, Morikawa Satoru, Kameda Makoto, Takahashi Kyoko
机构信息
Department of Food Science and Nutrition, School of Food Science and Nutrition, Mukogawa Women's University, Nishinomiya, Japan.
Department of Pediatrics, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan.
出版信息
Int Arch Allergy Immunol. 2023;184(12):1203-1215. doi: 10.1159/000533332. Epub 2023 Aug 30.
INTRODUCTION
Oral immunotherapy (OIT) imposes a burden on parents and their children with food allergies (FAs). We already developed a questionnaire for OIT-related Parental Burden (OIT-PB) scale. However, the previous questionnaire had some problems. This study modified OIT-PB and verified its reliability and validity.
METHODS
A 20-item draft covering the physical and mental burdens caused by OIT was prepared jointly with multiple allergists. The Food Allergy Quality of Life Questionnaire-Parental Burden (FAQLQ-PB) and Stress Response Scale-18 (SRS-18) were used to verify concurrent validity. A questionnaire survey was administered during treatment to parents of FA children who had started OIT for the first time. An additional OIT-PB survey was performed at one specific institution 1 week after the posttreatment survey.
RESULTS
The responses of 64 of the 76 recruited parents were analyzed. Of the 20 questions, 1 item was excluded owing to the floor effect, 1 was excluded because its commonality was less than 0.2, and 2 were excluded because their factor loading values were less than 0.4. Factor analysis was used to classify the OIT-PB into the following 4 subscales: "burden caused by adherence to treatment plan," "anxiety about symptom-induced risk," "burden due to patient's eating behavior," and "anxiety about treatment effect." The Cronbach's α for all 16 items of the OIT-PB was 0.893; Cronbach's α for each subscale was 0.876, 0.898, 0.874, and 0.717. The re-test reliability coefficient was 0.864 (95% confidence interval [CI]: 0.720-0.937, p < 0.001). A significant positive correlation was found between the OIT-PB and FAQLQ-PB (R = 0.610 [95% CI: 0.422-0.747], p < 0.001) and the SRS-18 (R = 0.522 [95% CI: 0.306-0.687], p < 0.001). A significant negative correlation was found between the rate of increase in OIT food intake and the "anxiety about treatment effect" score (R = -0.355 [95% CI: -0.558-0.112], p < 0.001). Parents of children on the hen's egg OIT treatment scored higher on the "burden due to patient's eating behavior" subscale than did parents of children on the milk and wheat OIT treatment.
CONCLUSION
The burden of OIT experienced by parents can be broadly classified into four categories. The modified OIT-PB was able to evaluate them individually and was shown to have reliability and validity. This scale is expected to be useful in the development of OIT that considers not only therapeutic effect but also the burden experienced by FA children and their parents.
引言
口服免疫疗法(OIT)给患有食物过敏(FA)的儿童及其父母带来了负担。我们已经开发了一份关于OIT相关父母负担(OIT-PB)量表的问卷。然而,之前的问卷存在一些问题。本研究对OIT-PB进行了修改,并验证了其信效度。
方法
与多位过敏症专科医生共同编制了一份包含20个条目的初稿,涵盖OIT所导致的身心负担。使用食物过敏生活质量问卷-父母负担(FAQLQ-PB)和应激反应量表-18(SRS-18)来验证同时效度。在治疗期间对首次开始OIT的FA儿童的父母进行问卷调查。在治疗后调查1周后,在一个特定机构对同一批父母进行了额外的OIT-PB调查。
结果
对招募的76位父母中的64位的回答进行了分析。在20个问题中,1个问题因地板效应被排除,1个问题因共同性小于0.2被排除,2个问题因因子载荷值小于0.4被排除。采用因子分析将OIT-PB分为以下4个分量表:“遵循治疗计划导致的负担”、“对症状诱发风险的焦虑”、“因患者饮食行为导致的负担”以及“对治疗效果的焦虑”。OIT-PB所有16个条目的克朗巴哈α系数为0.893;每个分量表的克朗巴哈α系数分别为0.876、0.898、0.874和0.717。重测信度系数为0.864(95%置信区间[CI]:0.720 - 0.937,p < 0.001)。发现OIT-PB与FAQLQ-PB(R = 0.610 [95% CI:0.422 - 0.747],p < 0.001)以及SRS-18(R = 0.522 [95% CI:0.306 - 0.687],p < 0.001)之间存在显著正相关。发现OIT食物摄入量的增加率与“对治疗效果的焦虑”得分之间存在显著负相关(R = -0.355 [95% CI:-0.558 - 0.112],p < 0.001)。接受鸡蛋OIT治疗的儿童的父母在“因患者饮食行为导致的负担”分量表上的得分高于接受牛奶和小麦OIT治疗的儿童的父母。
结论
父母所经历的OIT负担可大致分为四类。修改后的OIT-PB能够分别对这些负担进行评估,并显示出具有信效度。该量表有望在开发不仅考虑治疗效果,还考虑FA儿童及其父母所经历负担的OIT中发挥作用。